Last reviewed · How we verify
NCT04536558: OFFER
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study
Phase 3 trial testing olanzapine plus fosaprepitant-based triple regimen in Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy in 352 participants. Status unknown.
1 February 2021
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 352 |
| Start date | 1 October 2020 |
| Primary completion | 1 February 2021 |
| Estimated completion | 30 March 2021 |
| Sites | 18 locations across China |
Drugs / interventions tested
- olanzapine plus fosaprepitant-based triple regimen — full drug profile →
- placebo plus fosaprepitant-based triple regimen — full drug profile →
Conditions studied
- Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy — all drugs for Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, any sex, with Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, randomized, controlled, double-blind, phase III study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).
Zhao Y, Yang Y, Gao F, Hu C, et al · · 2023 · cited 27× · PMID 36712888 · DOI 10.1016/j.eclinm.2022.101771
Verify or expand the search:
- PubMed search for NCT04536558
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04536558 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 2 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04536558.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing